EU/3/16/1712

About

This medicine is now known as ziritaxestat.

On 29 August 2016, orphan designation (EU/3/16/1712) was granted by the European Commission to Galapagos NV, Belgium, for 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-alpha]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile for the treatment of idiopathic pulmonary fibrosis.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in April 2021 on request of the Sponsor.

Key facts

Active substance
2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-alpha]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile (ziritaxestat)
Disease / condition
Treatment of idiopathic pulmonary fibrosis
Date of first decision
29/08/2016
Outcome
Withdrawn
EU designation number
EU/3/16/1712

Review of designation


The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Galapagos N.V.
Generaal De Wittelaan L11 A3
2800 Mechelen Antwerp
Belgium
Tel. +32 1534 2900
E-mail: medicalinfo@glpg.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating